NASDAQ:ERYP ERYTECH Pharma - ERYP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $1.20 -0.08 (-6.25%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.08▼$1.3050-Day Range$0.33▼$1.3852-Week Range$0.30▼$2.18Volume39,969 shsAverage Volume83,314 shsMarket Capitalization$37.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ERYTECH Pharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.78 out of 5 starsMedical Sector1027th out of 1,028 stocksBiological Products, Except Diagnostic Industry168th out of 168 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for ERYTECH Pharma. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.22% of the outstanding shares of ERYTECH Pharma have been sold short.Short Interest Ratio / Days to CoverERYTECH Pharma has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ERYTECH Pharma has recently increased by 45.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldERYTECH Pharma does not currently pay a dividend.Dividend GrowthERYTECH Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERYP. Previous Next 1.7 News and Social Media Coverage News SentimentERYTECH Pharma has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ERYTECH Pharma this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ERYTECH Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.94% of the stock of ERYTECH Pharma is held by insiders.Percentage Held by InstitutionsOnly 4.79% of the stock of ERYTECH Pharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ERYTECH Pharma are expected to decrease in the coming year, from ($0.43) to ($0.93) per share.Price to Book Value per Share RatioERYTECH Pharma has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ERYTECH Pharma (NASDAQ:ERYP) StockERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.Read More Receive ERYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ERYP Stock News HeadlinesFebruary 1, 2023 | msn.comTelecoms, Natural Resources Lead European Equities Lower in Wednesday TradingJanuary 30, 2023 | msn.comEuropean Equities Start the Week Modestly Higher Amid German GDP ContractionFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 20, 2023 | msn.comEuropean Equities Nudge Lower in Friday Trading, With ADRs Ending Week FlatJanuary 9, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _December 31, 2022December 27, 2022 | msn.comEuropean Equities Broadly Flat Amid End of Chinese COVID-19 Quarantine RestrictionsDecember 21, 2022 | msn.comEuropean Equities Follow US Markets Higher in Wednesday TradingDecember 17, 2022 | msn.comEuropean Equities Sharply Lower With Pharma, Telecoms Most Active SectorsFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 6, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _November 30, 2022December 6, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _October 30, 2022November 21, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the Third Quarter of 2022November 21, 2022 | finance.yahoo.comERYTECH Provides Business and Financial Update for the Third Quarter of 2022November 15, 2022 | msn.comEuropean Markets Move Higher Helped by Upbeat US Inflation DataNovember 11, 2022 | msn.comEuropean ADRs Move Slightly Lower in Friday TradingNovember 8, 2022 | msn.comEuropean ADRs Move Higher in Tuesday Trading, Adding to Monday's GainsNovember 2, 2022 | msn.comEuropean ADRs Nudge Lower in Wednesday TradingOctober 21, 2022 | seekingalpha.comERYP ERYTECH Pharma S.A.October 13, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Announces Receipt of Nasdaq NoticeOctober 13, 2022 | finance.yahoo.comERYTECH Announces Receipt of Nasdaq NoticeOctober 10, 2022 | msn.comEuropean ADRs Move Lower in Monday TradingOctober 5, 2022 | finance.yahoo.comErytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's WhyOctober 4, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _September 30, 2022September 12, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the First Half of 2022September 12, 2022 | finance.yahoo.comERYTECH Provides Business and Financial Update for the First Half of 2022September 6, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _August 31, 2022September 6, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _July 31, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ERYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ERYP Company Calendar Today2/05/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERYP CUSIPN/A CIK1624422 Webwww.erytech.com Phone(347) 874-4438Fax33-4-78-75-56-29Employees196Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.57 Current Ratio2.25 Quick RatioN/A Sales & Book Value Annual Sales$4.95 million Price / Sales7.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book1.38Miscellaneous Outstanding Shares31,020,000Free Float30,417,000Market Cap$37.23 million OptionableNot Optionable Beta2.64 Key ExecutivesGil BeyenChief Executive Officer & DirectorEric SoyerChief Operating & Financial OfficerStewart CraigChief Technical OfficerIman El-HariryChief Medical OfficerJérôme BaillyChief Quality Officer & Deputy General ManagerKey CompetitorsTScan TherapeuticsNASDAQ:TCRXCardiol TherapeuticsNASDAQ:CRDLAVROBIONASDAQ:AVROEvaxion Biotech A/SNASDAQ:EVAXFreeline TherapeuticsNASDAQ:FRLNView All Competitors ERYP Stock - Frequently Asked Questions How have ERYP shares performed in 2023? ERYTECH Pharma's stock was trading at $0.3301 at the beginning of the year. Since then, ERYP stock has increased by 263.6% and is now trading at $1.2001. View the best growth stocks for 2023 here. When is ERYTECH Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our ERYP earnings forecast. What other stocks do shareholders of ERYTECH Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD). When did ERYTECH Pharma IPO? (ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager. What is ERYTECH Pharma's stock symbol? ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP." Who are ERYTECH Pharma's major shareholders? ERYTECH Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ERYTECH Pharma? Shares of ERYP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ERYTECH Pharma's stock price today? One share of ERYP stock can currently be purchased for approximately $1.20. How much money does ERYTECH Pharma make? ERYTECH Pharma (NASDAQ:ERYP) has a market capitalization of $37.23 million and generates $4.95 million in revenue each year. How many employees does ERYTECH Pharma have? The company employs 196 workers across the globe. How can I contact ERYTECH Pharma? ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The official website for the company is www.erytech.com. The company can be reached via phone at (347) 874-4438, via email at investors@erytech.com, or via fax at 33-4-78-75-56-29. This page (NASDAQ:ERYP) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.